Expression and immunogenicity of NY‑ESO‑1 in colorectal cancer
- Authors:
- Published online on: April 28, 2017 https://doi.org/10.3892/etm.2017.4405
- Pages: 3581-3585
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Serum assays of NY-ESO-1 antibodies provide a guide to discriminate between patients who suffer from different types of cancer. In the present study, the expression of NY‑ESO‑1 was detected with the aim to identify a novel tumor antigen in colorectal cancer (CRC). Sera were obtained from 89 healthy individuals and 236 patients with CRC with stage I, II, III and IV tumors. The NY‑ESO‑1 autoantibody levels were determined using an enzyme‑linked immunosorbent assay. The mRNA and protein expression levels of NY‑ESO‑1 were detected using reverse transcription‑polymerase chain reaction and immunohistochemistry, respectively, in 60 CRC and paired adjacent non‑tumor tissues. NY‑ESO‑1 antibody was detected in 40 of the 236 (16.9%) patients with CRC. The NY‑ESO‑1 antibody combined with carcinoembryonic antigen enhanced the sensitivity, from 52.1 to 62.7%, of the diagnosis of CRC. The frequency of antibody positivity increased with the TNM cancer stage (8.8 vs. 28.3% in stages I+II and III+IV, respectively). The mRNA and protein expression levels of NY‑ESO‑1 were significantly higher in CRC tissue than in adjacent non‑tumor tissue. In conclusion, NY‑ESO‑1 is frequently expressed in CRC with the capacity of inducing a humoral immune response in CRC patients, exhibiting the potential to be a promising biomarker for CRC.